NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) .


7089 Background: NGR-hTNF exploits the tumor-homing peptide NGR for selectively targeting tumor necrosis factor to tumor blood vessels. METHODS Here we report the long-term results of a phase II trial testing NGR-hTNF in 57 MPM patients (pts) who had failed a pemetrexed-based regimen. NGR-hTNF was given as 1-hour infusion at 0.8 µg/m2 every 3 weeks (q3w… (More)